Incidence and Predictors of HBsAg Loss in Treatment-Naïve Children With Immune-Tolerant Chronic Hepatitis B After Antiviral Therapy
Journal of the Pediatric Infectious Diseases Society · 2025
DOI: 10.1093/jpids/piaf083 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Pediatric Infectious Diseases Society, 2025. Verfasst von Yi Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Maternal and Child Health, Xiangya School of Public Health, Central South University, Changsha 410078, China. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis B, Chronic, Hepatitis B Surface Antigens, Immune Tolerance. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Natural Science Foundation of Hunan Province, National Natural Science Foundation of China.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
There are no established recommendations for the most suitable treatment of children with immune-tolerant chronic hepatitis B (CHB). To evaluate the clinical outcome of combination therapy among treatment-naïve children with immune-tolerant CHB, we conducted this study.
Methods
We retrospectively identified pediatric patients who were diagnosed with immune-tolerant CHB and who received combination therapy with interferon-alpha or peginterferon-alpha-2a plus entecavir at Hunan Children’s Hospital between August 2014 and April 2023. A total of 106 patients were ultimately enrolled in the study. Complete clinical data were collected for all the enrolled patients. The associations between baseline characteristics and HBsAg loss were assessed using Cox proportional hazards regression. Restricted cubic spline (RCS) plots were constructed to portray the association between HBsAg loss and patient age.
Results
After a median follow-up of 87 weeks, 23.5% (25/106) of the participants achieved sustained HBsAg loss, with a cumulative incidence of 44.9%. Proportional hazard regression indicated a significant association between achieving HBsAg loss and age, HBsAg level, and HBsAb level at baseline. The RCS plots suggested that, for pediatric patients, initiating antiviral therapy for immune-tolerant CHB might be most beneficial when they are less than 5 years old. Seventy-five (70.8%) patients experienced adverse events (AEs) following interferon therapy, with no severe AEs leading to treatment discontinuation.
Conclusions
The combination therapy led to favorable clinical outcomes for children with immune-tolerant CHB. Moreover, young age and low HBsAg and high HBsAb levels at baseline are predictors of a clinical cure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Maternal and Child Health, Xiangya School of Public Health, Central South University, Changsha 410078, China.
- Department of Hepatopathy Center, Hunan Children's Hospital, Changsha 410007, China.
ORCID-Profile: Songxu Peng
Förderung
- Natural Science Foundation of Hunan Province
- National Natural Science Foundation of China
Zitieren
APA
Xu, Y., Li, S., Gu, Y., Yang, M., Li, S., Ye, L., & Peng, S. (2025). Incidence and Predictors of HBsAg Loss in Treatment-Naïve Children With Immune-Tolerant Chronic Hepatitis B After Antiviral Therapy. Journal of the Pediatric Infectious Diseases Society. https://doi.org/10.1093/jpids/piaf083
Vancouver
Xu Y, Li S, Gu Y, Yang M, Li S, Ye L, et al. Incidence and Predictors of HBsAg Loss in Treatment-Naïve Children With Immune-Tolerant Chronic Hepatitis B After Antiviral Therapy. Journal of the Pediatric Infectious Diseases Society. 2025. doi:10.1093/jpids/piaf083
BibTeX
@article{Xu2025,
author = {Xu, Yi and Li, ShuangJie and Gu, Yingping and Yang, Meng and Li, Sisi and Ye, Ling and Peng, Songxu},
title = {Incidence and Predictors of HBsAg Loss in Treatment-Naïve Children With Immune-Tolerant Chronic Hepatitis B After Antiviral Therapy},
journal = {Journal of the Pediatric Infectious Diseases Society},
year = {2025},
doi = {10.1093/jpids/piaf083}
}
EUVIMED